Géraldine Androdias

4PUBLICATIONS
15CO-AUTHORS
Nanotoxicology, health and safetyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 18, 2026
Opportunistic infections in people treated with natalizumab - beyond PML.

|Apr 05, 2026
Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.

Chloe Pierret, Geraldine Androdias, Christine Lebrun-Frenay

|May 26, 2025
Should disease-modifying therapy be discontinued in older patients with stable MS after long-term clinical and radiological stability? Yes.

Géraldine Androdias, Bruno Stankoff

|Dec 21, 2024
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.

Géraldine Androdias, Jan D Lünemann, Elisabeth Maillart

Pageof 1

Frequent Collaborators

1 joint publications

Jan D Lünemann

1 joint publications

Arlette L Bruijstens

1 joint publications

Gabriel Bsteh

1 joint publications

Alvaro Cobo-Calvo